Contineum Therapeutics's top three insider shareholders as of March 23, 2026 are Daniel S. Lorrain (Chief Scientific Officer, 151.88K shares), Venture Capital Vi, L.P. Versant (TenPercentOwner, 148.31K shares), Carmine N. Stengone (Ceo And President, 14.95K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Daniel S. Lorrain | Chief Scientific Officer | 151,882 | 0 | 02 Mar, 2026 |
| Venture Capital Vi, L.P. Versant | 0 | 148,312 | 11 Apr, 2024 | |
| Carmine N. Stengone | Ceo And President | 14,954 | 0 | 26 Feb, 2026 |
| Stephen L. Huhn | Cmo Sr Vp, Clinical Dev. | 12,800 | 0 | 14 Aug, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Mar, 2026 | Tim Watkins | Class A Common Stock | A | 3,611 | $4.50 | 3,611 | D | M |
| 02 Mar, 2026 | Daniel S. Lorrain | Class A Common Stock | D | 4,170 | $15.01 | 151,882 | D | S |
| 02 Mar, 2026 | Tim Watkins | Class A Common Stock | D | 3,611 | $15.02 | 0 | D | S |
| 02 Mar, 2026 | Tim Watkins | Stock Option (right to buy) | D | 3,611 | $0.00 | 249,167 | D | M |
| 24 Feb, 2026 | Daniel S. Lorrain | Class A Common Stock | A | 4,300 | $1.01 | 160,352 | D | M |
| 24 Feb, 2026 | Carmine N. Stengone | Class A Common Stock | A | 4,400 | $1.26 | 19,354 | D | M |
| 24 Feb, 2026 | Carmine N. Stengone | Class A Common Stock | D | 4,400 | $16.02 | 14,954 | D | S |
| 24 Feb, 2026 | Daniel S. Lorrain | Class A Common Stock | D | 4,300 | $16.03 | 156,052 | D | S |
| 25 Feb, 2026 | Carmine N. Stengone | Class A Common Stock | A | 2,700 | $1.26 | 17,654 | D | M |
| 25 Feb, 2026 | Daniel S. Lorrain | Class A Common Stock | A | 3,824 | $1.01 | 159,876 | D | M |
| 25 Feb, 2026 | Daniel S. Lorrain | Class A Common Stock | D | 3,824 | $16.01 | 156,052 | D | S |
| 25 Feb, 2026 | Carmine N. Stengone | Class A Common Stock | D | 2,700 | $16.02 | 14,954 | D | S |
| 24 Feb, 2026 | Carmine N. Stengone | Stock Option (right to buy) | D | 4,400 | $0.00 | 123,617 | D | M |
| 25 Feb, 2026 | Carmine N. Stengone | Stock Option (right to buy) | D | 2,700 | $0.00 | 120,917 | D | M |
| 24 Feb, 2026 | Daniel S. Lorrain | Stock Option (right to buy) | D | 4,300 | $0.00 | 71,130 | D | M |
| 25 Feb, 2026 | Daniel S. Lorrain | Stock Option (right to buy) | D | 3,824 | $0.00 | 67,306 | D | M |
| 19 Feb, 2026 | Daniel S. Lorrain | Class A Common Stock | A | 100 | $1.01 | 156,152 | D | M |
| 19 Feb, 2026 | Daniel S. Lorrain | Class A Common Stock | D | 100 | $16.00 | 156,052 | D | S |
| 19 Feb, 2026 | Daniel S. Lorrain | Stock Option (right to buy) | D | 100 | $0.00 | 75,430 | D | M |
| 11 Feb, 2026 | Daniel S. Lorrain | Class A Common Stock | A | 400 | $1.01 | 156,452 | D | M |